InflammoPharmacology

, Volume 7, Issue 3, pp 207–217 | Cite as

Multi-drug strategies are necessary to inhibit the synergistic mechanism causing tissue damage and organ failure in post infectious sequelae

  • Isaac Ginsburg
Article
Received:
Revised:
Accepted:

Abstract

—The paper discusses the principal evidence that supports the concept that cell and tissue injury in infectious and post-infectious and inflammatory sequelae might involve a deleterious synergistic interaction among microbial- and host-derived pro-inflammatory agonists. Experimental models had proposed that a rapid cell and tissue injury might be induced by combinations among subtoxic amounts of three major groups of agonists generated both by microorganisms and by the host’s own defense systems. These include: (1) oxidants: Superoxide, H2O2, OH’, oxidants generated by xanthine-xanthine-oxidase, ROO; HOC1, NO, OONO’—, (2) the membrane-injuring and perforating agents, microbial hemolysins, phospholipases A2 and C, lysophosphatides, bactericidal cationic proteins, fatty acids, bile salts and the attack complex of complement a, certain xenobics and (3) the highly cationic proteinases, elastase and cathepsin G, as well as collagenase, plasmin, trypsin and a variety of microbial proteinases. Cell killing by combinations among the various agonists also results in the release of membrane-associated arachidonate and metabolites. Cell damage might be further enhanced by certain cytokines either acting directly on targets or through their capacity to prime phagocytes to generate excessive amounts of oxidants. The microbial cell wall components, lipoteichoic acid (LTA), lipopolysaccharides (LPS) and peptidoglycan (PPG), released following bacteriolysis, induced either by cationic proteins from neutrophils and eosinophils or by beta lactam antibiotics, are potent activators of macrophages which can release oxidants, cytolytic cytokines and NO. The microbial cell wall components can also activate the cascades of coagulation, complement and fibrinolysis. All these cascades might further synergize with microbial toxins and metabolites and with phagocyte-derived agonsits to amplify tissue damage and to induce septic shock, multiple organ failure, ‘flesh-eating’ syndromes, etc. The long persistence of non-biodegradable bacterial cell wall components within activated macrophages in granulomatous inflammation might be the result of the inactivation by oxidants and proteinases of bacterial autolytic wall enzymes (muramidases). The unsuccessful attempts in recent clinical trials to prevent septic shock by the administration of single antagonists is disconcerting. It does suggest however that, since tissue damage in post-infectious syndromes is most probably the end result of synergistic interactions among a multiplicity of agents, only agents which might depress bacteriolysis in vivo and ‘cocktails’ of appropriate antagonists, but not single antagonists, if administered at the early phases of infection especially to patients at high risk, might help to control the development of post-infectious syndromes. However, the use of adequate predictive markers for sepsis and other post-infectious complications is highly desirable. Although it is conceivable that anti-inflammatory strategies might also be counter-productive as they might act as ‘double-edge swords’, intensive investigations to devise combination therapies are warranted. The present review also lists the major anti-inflammatory agents and strategies and combinations among them which have been proposed in the last few years for clinical treatments of sepsis and other post-infectious complications.

Key words

Inflammation Infection Synergism Bacteriolysis Sepsis Organ failure Anti-inflammatories 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baue, A. E. (1992). The horror autotoxicus and multiple-organ failure, Arch. Surg. 127, 1451–1462.PubMedGoogle Scholar
  2. Baue, A. E. (1998). Systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), multiple organ failure (MOF): are we winning the battle?, Shock 10, 79–89.PubMedCrossRefGoogle Scholar
  3. Baue, A. E., Berlot, A. and Gullo, A. (Eds) (1998). Sepsis and Organ Dysfunction: Epidemiology and Scoring Systems, Pathophysiology and Therapy. Springer Verlag, Milan.Google Scholar
  4. Baird, B. R., Cherionis, J. et al. (1986). Oxygen metabolites and neutrophil elastase synergistically cause edematous injury in isolated rat lungs, J. Appl. Physiol. 161, 224–2229.Google Scholar
  5. Dan, P., Nizan, D. et al. (1996). H2O2 degrades cell surface proteoglycans and exposes the cells to lysis by Phospholipase A2: A novel mechanism for cell damage in inflammatory processes, FEBS Letters 383, 57–78.CrossRefGoogle Scholar
  6. Faist, E. and Kim, C. (1998). Therapeutic immunomodulatory approach to control the systemic inflammatory responce syndrome and prevention of sepsis, New Horiz. 6 (Suppl), 97–102.Google Scholar
  7. Ferrante, A., Kowanko, I. C. and Bates, E. J. (1992). Mechanisms of host tissue damage by cytokine-activated neutrophils, in: Granulocyte Responses to Cytokines: Basic Clinical Research, Coffey, R. G. (Ed.), pp. 499–521. Marcel Dekker, New York.Google Scholar
  8. Fisher, C. J. and Zheng, Y. (1996). Potential strategies for inflammatory mediator manipulations: Retrospect and prospect, World J. Surg. 20, 447–451.PubMedCrossRefGoogle Scholar
  9. Fujiata, H., Morita, I., Morita I., Ishikawa, K. and Sei-itsu, M. (1996). The synergistic effect of elastase and hydrogen peroxide on vascular endothelial cells. J. Atherosclerosis, Thrombosis 3, 32–38.Google Scholar
  10. Furies, D. G. (1998). Interferon-therapy for infectious complications of injury, Crit. Care Med. 26, 419–420.CrossRefGoogle Scholar
  11. Gallili, R., Yamin, A., Waksmann, Y., Ovadia, H., Weidenfield, J., Bar, J., Biegon and Mechoulam, R. (1997). Protection against septic shock and suppression of tumor necrosis factor and nitric oxide by dexacabinol (HU-211) a non-psychotropic canabinoid, J. Pharmacol. Exp. Then 283, 918–924.Google Scholar
  12. Ginsburg, I. (1972). Mechanisms of cell and tissue injury induced by group A streptococci: relation to post-streptococcal sequelae, J. Infect. Dis. 126, 294–340, 419-456.PubMedGoogle Scholar
  13. Ginsburg, I. (1979). The role of lysosomal factors of leukocytes in the biodegradation and storage of microbial constituents in infectious granulomas (a review), Front. Biol. 4, 327–406.Google Scholar
  14. Ginsburg, I. (1987). Cationic polylectrolytes: A new look into their possible roles as opsonins, as stimulators of the respiratory burst in leukocytes, in bacteriolysis and as modulators of immune complex diseases, Inflammation 11, 489–515.PubMedCrossRefGoogle Scholar
  15. Ginsburg, I. (1988). The biochemistry of bacteriolysis: Facts, paradoxes and myths, Microbiol. Sci. 5, 137–142.PubMedGoogle Scholar
  16. Ginsburg, I.(1989). Bacteriolysis is inhibited by hydrogen peroxide and proteases, Agents Actions 28, 238–242.PubMedCrossRefGoogle Scholar
  17. Ginsburg, I. (1994). Can hemolytic streptococci be considered “forefathers” of modern phagocytes? Both cell types freely migrate in tissues and destroy host cells by a “synergistic cross-talk” among their secreted agonists, Comp. Biochem. Physiol. 109C, 147–158.Google Scholar
  18. Ginsburg, I. and Kohen, R. (invited Review) (1995). Cell damage in inflammatory and infectious sites might involve a coordinated “cross-talk” among oxidants, microbial hemolysins and amphiphiles, cationic proteins, phospholipases, fatty acids, proteinases and cytokines (an overview), Free Rad. Res. 22, 489–517.Google Scholar
  19. Ginsburg, I. (1998). Could synergistic interactions among reactive oxygen species, proteinases, membrane-perforating enzymes, hydrolases, microbial hemolysins and cytokines be the main cause of tissue damage in infectious and inflammatory conditions?, Medical Hypothesis 51, 337–374.CrossRefGoogle Scholar
  20. Ginsburg, I. and Barak, To be published.Google Scholar
  21. Ginsburg, I. and Sadovnic, M. (1998). Gamma globulin, Evan’s blue, aprotinin, tetracycline and antioxidants protect epithelial cells against damage induced by synergism among streptococcal hemolysins, oxidants and proteinases: relation to the prevention of septic shock, FEMS Immunol. Med. Microbiol. 22, 247–256.PubMedGoogle Scholar
  22. Ginsburg, I., Sadovnic, M., Sallon, S., Milo-Goldzweig, I., Mechoulam, R., Breurer, A., Gibbs, D.F., Varani, J., Roberts, S., Cleator, E. and Singh, N. (1999). PADMA-28, a traditional Tibetan herbal preparation inhibits the respiratory burst in human neutrophils, the killing of epithelial cells by mixtures of oxidants, and pro-inflammatory agonists and peroxidation of lipids, Inflammopharmacology 7, 47–62.PubMedGoogle Scholar
  23. Ginsburg, I., Ward, P. A. and Varani, J. (1999). Can we learn from the pathogenetic properties of group A hemolytic streptococci how tissues are destroyed and organs fail in post-infectious and inflammatory sequelae?, FEMS Immunol. Med. Microbiol. 25, 325–338.PubMedCrossRefGoogle Scholar
  24. Hack, C. E. E., Aarden, L. A. and Thijt, L. G. (1997). Role of cytokines in sepsis, Adv. Immunol. 66, 101–195.PubMedGoogle Scholar
  25. Holzheimer, R. G. (1998). The significance of endotoxin release in experimental and clinical sepsis, in surgical patients: evidence for antibiotic-induced endotoxin release?, Infection 26, 77–84.PubMedGoogle Scholar
  26. Horn, D. L., Opal, S. M. and Lomastro, E. (1996). Antibiotics, cytokines, and endotoxin: a complex and evolved relationship in Gram-negative sepsis, Scand. J. Infect. Dis. 101 (Suppl. 1), 19–13.Google Scholar
  27. Kiriyama, T., Mityake, Y., Kobayshi, K., Yoshiga, K., Takada, K. and Suginaka, H. (1987). Effects of mucopolysaccharides on penicillin-induced lysis of Staphylococcus aureus, J. Med. Microbiol. 24, 325–331.PubMedGoogle Scholar
  28. Klebanoff, S. F., Kinsella, M. G. and Wight, T. N. (1983). Degradation of endothelial matrix heparan sulfate proteoglycan by elastase and the myeloperoxidase-H2O2 -chloride system, Am. J. Physiol. 192, 907–917.Google Scholar
  29. Lichtenstein, A. K., Ganz, T., Selsted, M. and Lehrer, R. I. (1988). Cytolysis mediated by hydrogen peroxide combined with peptide defensins, Cellular Immunology 114, 104–116.PubMedCrossRefGoogle Scholar
  30. Liu, M. and Slutzki, A. S. (1997). Anti-inflammatory therapies: application of molecular biology techniques in intensive care medicine, Intensive Care Med. 23, 718–731.PubMedCrossRefGoogle Scholar
  31. Luckacks, N. W. and Ward, P. A. (1996). Inflammatory mediators, cytokines, and adhesion molecules in pulmonary inflammation and injury, Adv. Immunol. 62, 257–304.Google Scholar
  32. McGowan, S. E. and Murry, J. J. (1987). Direct effect of neutrophil oxidants and elastase-induced extra-cellular matrix proteolysis, Am. Rev. Resp. Dis. 125, 1286–1293.Google Scholar
  33. Mendis, A. H. W., Venaille, T. J. and Roobinson, T. N. (1990). Study of human epithelial cell detachment and damage: effect of protease and oxidants, Immunol. Cell Biol. 68, 95–105.PubMedCrossRefGoogle Scholar
  34. Nasraway, S. A. (1999). Sepsis research; We must change course, Crit. Care Med. 27, 427–430.PubMedCrossRefGoogle Scholar
  35. Natanson, C. (1997). Anti-inflammatory therapies to treat septic shock: A reassessment, Editorial, Crit. Care Med. 25, 1095–1100.PubMedCrossRefGoogle Scholar
  36. Opal, S. M. and Liu, R. L. Jr. (1998). Antiendotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions, Drugs 55, 497–508.PubMedCrossRefGoogle Scholar
  37. Periti, A. and Mazzeti, A. (1998). Antibiotic-induced release of bacterial cell-wall components in the pathogenesis of sepsis and septic chock: a review, J. Chemother. 10, 427–448.PubMedGoogle Scholar
  38. Pinsky, M. R. (1996). Organ-specific therapy in critical illness: interfacing molecular mechanisms with physiological interventions, J. Crit. Care 11, 95–107.PubMedCrossRefGoogle Scholar
  39. Ralston, D. R. and St. John, R. C. (1996). Immunotherapy for sepsis, Clinics in Chest Medicine 17, 307–317.PubMedCrossRefGoogle Scholar
  40. Rice-Evans, C. A. and Diplock, A. T. (1993). Current status of antioxidant therapy, Free Rad. Biol. Med. 15, 77–96.PubMedCrossRefGoogle Scholar
  41. Rodell, T. C., Cherionis, J. C., Ohnemous, J. C., Pirmatei, D. J. and Repine, J. E. (1987). Xanthine oxidase-derived toxic oxygen metabolites contribute to lung injury from neutrophil elastase, Chest 93, 146–153.Google Scholar
  42. Sallon, S. and Beer, G. (1998). The efficacy of PADMA-28, a herbal preparation, in the treatment of intermittent claudication: a controlled double-blind polot study with objective assessment of chronic occlusive arterial disease patients, J. Vasc. Invest. 4, 129–136.Google Scholar
  43. Schlag, G. and Redl, H. (Eds) (1999). Shock, Sepsis and Organ Failure-Scavenging of Nitric Oxide and Inhibition of its Products. Springer-Verlag, Berlin.Google Scholar
  44. Servansky, J. E., Snaked, G., Novogrodzli, A. and Levitzki, A. (1997). Tyrosine AG 556 improves survival and reduces multiorgan failure in canine Escherichia coli peritonitis, J. Clin. Invest. 99, 1966–1973.CrossRefGoogle Scholar
  45. Stevens, D. L. (1995). Streptococcal toxic-shock syndrome: spectrum of diseases, pathogenesis and new concepts of treatment, Emerg. Infect. Dis. 1, 69–78.PubMedCrossRefGoogle Scholar
  46. Triujillo, M. H., Guerrero, J., Fragachan, C. and Fernandez, M. A. (1998). Pharmacological antidotes in clinical care medicine: a practical guide for drug administration, Clin. Care Med. 26, 377–391.CrossRefGoogle Scholar
  47. Tuomanen, E. and Tomasz, A. (1984). Protection by D-amino acids against growth inhibition and lysis caused by beta-lactam antibiotics, Antimicrobial Agents Chemother. 26, 414–416.Google Scholar
  48. Verhoef, J., Hustinx, W. M. N. et al. (1996). Issues in the adjunct therapy of severe sepsis, J. Antimicrobial Chemother. 138, 167–182.CrossRefGoogle Scholar
  49. Vincent, J. L. (1997). Clinical trials in sepsis: Where do we stand?, J. Crit. Care 12, 3–6.PubMedCrossRefGoogle Scholar
  50. Wecke, J., Kwa, E., Lahav, M. and Ginsburg, I. (1987). Suppression of penicillin-induced bacteriolysis of staphylococci by some anticoagulants, J. Antimicrob. Chemother. 20, 47–55.PubMedCrossRefGoogle Scholar
  51. Wecke, J., Franz M. and Giesbrecht, P. (1990). Inhibition of the bacteriolytic effect of beta-lactam antibiotics on Staphylococcus aureus by the polyanionic drugs suramine and Evans’ blue, AMPIS 98, 71–81.Google Scholar
  52. Weiss, S. (1989). Tissue destruction by neutrophils, New Engl. J. Med. 320, 365–376.PubMedCrossRefGoogle Scholar
  53. Weiss, D. J., Curnutte, J. T. and Regiant, S. (1986). Neutrophil-mediated solubilization of subendothelial matrix: oxidative and non-oxidative mechanisms of proteolysis used by normal and chronic granulomatous disease phagocytes, J. Immunol. 136, 636–641.PubMedGoogle Scholar
  54. Wheeler, A. P. and Bernard, G. R. (1996). Application of molecular biology and biotechnology: antibody therapy of sepsis, J. Crit. Care 11, 77–94.PubMedCrossRefGoogle Scholar
  55. Wheeler, A. P. and Bernard, G. R. (1999). Treating patients with severe sepsis, New Engl. J. Med. 340, 207–214.PubMedCrossRefGoogle Scholar
  56. Yao, Y. M., Redl, H. and Schlag, G. (1998). The inflammatory basis of trauma/shock-associated multiple organ failure, Inflamm. Res. 47, 201–210.PubMedCrossRefGoogle Scholar
  57. Zanetti, G. and Glauser, M. P. (1997). Prevention and treatment of sepsis and septic shock, Curr. Opnion. Infect. Dis. 10, 139–141.CrossRefGoogle Scholar

Copyright information

© VSP 1999

Authors and Affiliations

  • Isaac Ginsburg
    • 1
  1. 1.Department of Oral BiologyHebrew University-Hadassah Faculty of Dental MedicineJerusalemIsrael

Personalised recommendations